Turnstone Biologics (TSBX) Stock Price, News & Analysis

Company Overview

Turnstone Biologics, Inc. (NASDAQ: TSBX) is a clinical‐stage biotechnology company dedicated to developing oncolytic viral therapies that harness and enhance the body’s immune system to fight cancer. By leveraging its proprietary Viral Immunotherapy Platform (VIP), Turnstone engineers natural viruses to selectively infect and kill tumor cells while stimulating robust anti‐tumor immune responses. The company’s lead investigational therapy, V937, is derived from Coxsackievirus A21 and is being evaluated in multiple clinical trials for solid tumors, including melanoma and bladder cancer, both as a monotherapy and in combination with immune checkpoint inhibitors.

Turnstone’s research and development efforts focus on both intrinsic and extrinsic tumor vulnerabilities. Its platform allows for the rapid design and testing of viral vectors that can carry therapeutic payloads or express immunomodulatory proteins directly within the tumor microenvironment. This approach is intended to overcome resistance mechanisms that limit the efficacy of existing immunotherapies. In addition to V937, the company is advancing a pipeline of next‐generation candidates designed to optimize dosing, enhance systemic delivery and improve safety profiles.

Founded in 2009 and headquartered in Seattle, Washington, Turnstone Biologics operates research facilities in both the United States and the United Kingdom, enabling collaboration with leading academic institutions and biopharmaceutical partners. The company’s global footprint supports ongoing clinical studies in North America and Europe, and it has established strategic alliances with major industry players to explore combination regimens and broaden the potential application of its oncolytic platforms.

Turnstone’s leadership team combines expertise in virology, oncology and pharmaceutical development. Co‐founder and Chief Executive Officer Hassan F. Merheb brings extensive experience in gene therapy and viral vector engineering, while its board includes renowned immunologists and biotech entrepreneurs who guide the company’s strategic vision. Together, they aim to translate Turnstone’s innovative viral immunotherapies into new treatment options for patients with advanced cancers.

Key Stats

• Today's Range: $0.36 to $0.37
• 50-Day Range: $0.31 to $0.38
• 52-Week Range: $0.29 to $2.69
• Volume: 146,612 shs
• Average Volume: 278,940 shs
• Market Capitalization: $8.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.45
• Consensus Rating: Reduce

Turnstone Biologics Stock Analysis - MarketRank™

Turnstone Biologics scored higher than 52% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Turnstone Biologics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Turnstone Biologics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Turnstone Biologics are expected to grow in the coming year, from ($3.32) to ($0.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Turnstone Biologics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Turnstone Biologics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Turnstone Biologics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.52% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 91.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Turnstone Biologics does not currently pay a dividend.

Dividend Growth

Turnstone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.52% of the float of Turnstone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Turnstone Biologics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Turnstone Biologics has recently decreased by 91.26%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Turnstone Biologics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Turnstone Biologics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Turnstone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSBX Stock Analysis - Frequently Asked Questions

How have TSBX shares performed this year?

Turnstone Biologics' stock was trading at $0.4969 at the beginning of 2025. Since then, TSBX shares have decreased by 27.3% and is now trading at $0.3610.

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.25.

When did Turnstone Biologics IPO?

Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share.

How do I buy shares of Turnstone Biologics?

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Turnstone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Turnstone Biologics investors own include Cara Therapeutics (CARA), JPMorgan Chase & Co. (JPM), Avino Silver & Gold Mines (ASM), Bank of America (BAC), Intel (INTC) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSBX
• CIK: 1764974
• Web: turnstonebio.com
• Phone: 347-897-5988
• Fax: N/A
• Employees: 82
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Turnstone Biologics: $0.45
• High Price Target: $0.50
• Low Price Target: $0.40
• Potential Upside/Downside: +26.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -162.79%
• Return on Assets: -124.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.70
• Quick Ratio: 3.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.36 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 23,140,000
• Free Float: 15,712,000
• Market Cap: $8.26 million
• Optionable: Not Optionable
• Beta: 1.35